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Preeclampsia is one of the three leading causes of ma-
ternal morbidity and mortality worldwide, complicating 
around 2–8% of pregnancies (1). This disorder increases 
the chance of adverse perinatal outcomes, such as fetal 
growth restriction and preterm delivery (2). Both the 
women who develop preeclampsia and their babies are at 
increased risk of hypertension in later life. Moreover, 
women with a history of preeclampsia have an 8-fold 
greater risk of death from CVD (3). The American Heart 
Association has included preeclampsia as a risk factor in 
guidelines for preliminary risk evaluation for CVD in women 
(4). The cause of preeclampsia remains unknown; differ-
ent lines of evidence indicate that abnormal lipid metabo-
lism is involved in the pathogenesis; the acute atherosis 
seen in uteroplacental beds in preeclamptic women is one 
of these (5).
Cholesterol is an essential component required for 
both placental and fetal development as a precursor of 
metabolic mediators such as oxysterols (6). The sterol 
27-hydroxylase (CYP27A1), a ubiquitously expressed mito-
chondrial enzyme belonging to the cytochrome P450 fam-
ily, catalyzes the hydroxylation of cholesterol at C-27 to 
form 27-hydroxycholesterol (27-OHC) and cholestenoic 
acid (7). CYP27A1 is also involved in cholesterol efflux, the 
first and rate-limiting step of reverse cholesterol transport 
(RCT). RCT is defined as the transport of cholesterol 
from peripheral organs/macrophages to an acceptor in 
plasma, followed by its transfer to the liver in order to be 
eliminated/recycled. Overexpression of CYP27A1, as seen 
in Chinese hamster ovary cells expressing polyoma LT 
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antigen (CHOP) cells and macrophages (8, 9), results in 
enhanced cholesterol efflux. Indeed, the appearance of 
27-OHC may produce conformal changes in the plasma 
membrane and facilitate the release of cholesterol and 
27-OHC to an acceptor in plasma. The 27-OHC is also a 
ligand of the liver X-activated receptor, which regulates a 
number of genes involved in cholesterol homeostasis, in 
particular ABCA1 (8). Little is known about CYP27A1 ex-
pression in the placenta, and we are not aware of any study 
reporting placental 27-OHC concentrations.
Apolipoproteins are proteins that interact with lipids to 
form soluble lipid-complexes, allowing the transport of lip-
ids via the circulation. apoE is a major constituent of VLDLs 
and is an essential ligand for the uptake and clearance of 
atherogenic lipoproteins, playing important roles in ath-
erosclerosis by modifying inflammatory responses and fa-
cilitating cholesterol efflux from foam cells (10, 11). apoA1 
is a major apolipoprotein of HDL cholesterol (HDL-C) 
and is significantly involved in the regulation of lipid trans-
port and metabolism of HDL particles (12). apoAI binding 
protein (AIBP) is secreted from tissue and physically binds 
with apoAI (13). AIBP accelerates cholesterol efflux from 
endothelial cells to HDL-C, thereby regulating angiogene-
sis via alterations in the composition of the lipid rafts, pos-
sibly due to reduced caveolin-1 (CAV-1) and interference 
with vascular endothelial growth factor receptor (VEGFR)2 
signaling (14, 15). Alterations in angiogenic factors have 
been repeatedly observed in preeclamptic placentae (16) 
with decreased VEGF-A and VEGFR1 in the cytotrophoblast. 
Increased plasma apoE polymorphisms have been reported 
in women with preeclampsia (17, 18); however, findings 
relating to apoA1 measurements in preeclampsia are con-
flicting (19, 20). To date, it is not known whether AIBP is 
expressed in the placenta or altered in preeclampsia.
In our previous study with the same patients used in this 
study, no significant differences could be demonstrated be-
tween groups with regard to the maternal and umbilical 
venous (fetal) serum LDL cholesterol (LDL-C), HDL-C, 
total cholesterol (TC), and triglycerides (TGs). However, 
fetal serum concentrations were significantly lower com-
pared with maternal concentrations in both groups (21).
In a recent study of 2,924 nonpregnant individuals, 
where baseline assessments were compared with measure-
ments at a mean follow-up of 9.4 years, the addition of cho-
lesterol efflux to traditional risk factors was associated with 
improved discrimination/reclassification indexes of car-
diovascular risk (22). The authors suggested that choles-
terol efflux capacity may be a more important factor than 
simply HDL-C concentrations alone when assessing the risk 
of a cardiovascular event occurrence. Increased cholesterol 
efflux capacity was associated with a reduced cardiovascu-
lar risk (22).
We hypothesized that maternal and fetal cholesterol ef-
flux, as well as placental CYP27A1 expression, would be in-
creased in preeclampsia. This could be an attempt to 
remove cholesterol from cells and thus prevent further 
lipid peroxidation and subsequent oxidative stress, while 
simultaneously having an atheroprotective role, during 
pregnancy.
MATERIALS AND METHODS
Subjects and selection criteria
The study consisted of two groups of white European women 
(17 normotensive, 17 with preeclampsia; Table 1), where 
matched maternal, fetal, and placental samples were available. 
Detailed demographics and outcome data have previously been 
published (23). Back power calculations using our cholesterol 
efflux capacity data revealed an 85.5% power with an  of 0.5 to 
detect the differences observed. The study was approved by the 
Hospital Ethics Committee of the Nottingham University Hospi-
tals; written informed consent was obtained from each partici-
pant. Preeclampsia was defined as systolic blood pressure of 
140/90 mmHg on two occasions and proteinuria 300 mg/l, 
500 mg/day, or 2+ on a dipstick analysis of midstream urine 
after 20 weeks (24). The birthweight centile for each baby was 
computed, correcting for gestation age, sex, maternal parity, and 
BMI (25). Small-for-gestational-age (SGA) was defined as a cen-
tile below the 10th percentile, and appropriate-for-gestational-
age (AGA) when the individualized birthweight ratio was 
between the 10th and 90th percentile (26). All women who took 
part in this study were laboring and either delivered vaginally or 
by emergency Caesarean section; no differences were observed 
in any measurements between Caesarean section and vaginal 
deliveries.
Sample collection and measurements
Maternal venous blood samples were taken prior to delivery. 
Where possible, fetal blood samples were collected from the um-
bilical cord vein immediately after delivery of the placenta, as pre-
viously described (23). All blood samples were collected in EDTA 
(plasma) or plain tubes (serum).
Full-depth tissue biopsies were collected within 10 min of the 
placenta being delivered, as previously described (23), sampling 
half-way between the cord insertion and periphery of the pla-
centa, avoiding infarcts. The lipoproteins (LDL-C, HDL-C, TC, 
and TG) were previously measured in maternal and fetal serum 
from the same sample collection (21).
TABLE 1. Clinical and obstetric data of subject groups
Parameter NC (n = 17) PE (n = 17)
Age (years) 28.2 ± 7.2 31 ± 6.5
BMI at first visit (<14 weeks’  
gestation; kg/m2)
26.4 ± 5.5 24.8 ± 3.5
Smoking status
 Nonsmoker 9 (53) 11 (65)
 Smoker 8 (47) 6 (35)
Parity
 Nulliparous 11 (65) 10 (59)
 Multiparous 6 (35) 7 (41)
Maximum systolic blood pressure  
(mmHg)
114 ± 3.8 155 ± 3.8a
Maximum diastolic blood pressure  
(mmHg)
75 ± 2.1 97 ± 5.0a
Proteinuria (g/l), median  
[minimum, maximum]
— 1.0 [0.3, 9.4]
Gestational age at delivery (weeks) 40 ± 1.0 37.7 ± 1.8
Mean birthweight (g) 3439 ± 498 2993 ± 735a
Corrected birthweight centile 27.9 [17.5, 66.8] 35.1 [8.6, 76.3]
Caesarean section 4 (24) 13 (76)
Data represented as mean ± SD or median [IQR] as appropriate, 
except for smoking status, parity, Caesarean sections, and early-onset 
PE, which are shown as number (percentage). NC, normotensive 
control; PE, preeclampsia.
aP < 0.05 between NC and women with PE.
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Cholesterol efflux
Cholesterol efflux was determined in RAW264.7 cells (ATCC), 
as previously described (8), using maternal or fetal plasma as ac-
ceptors. Briefly, following labeling for 48 h with 0.2 Ci/ml [3H]
cholesterol (Anawa, Switzerland), cells were washed with PBS 
(pH 7.4), equilibrated for 18 h in OptiMem, and incubated for 
2 h in the presence or absence of 5% maternal or fetal plasma. 
The HDL-mediated cholesterol efflux was performed as described 
above, using 5% apoB-depleted plasma as the acceptor. For prep-
aration of apoB-depleted plasma, 40 l polyethylene glycol (20% 
in 200 mmol/l glycine buffer) were added to 100 l plasma, 
incubated at room temperature for 20 min, and the superna-
tant was recovered after centrifugation (10,000 rpm, 20 min, 
4°C), as described by Holzer et al. (27). To measure the ABCA1-
mediated efflux, the difference in efflux between control and 
8-bromoadenosine 3′,5′-cyclic monophosphate sodium salt-cAMP 
(8Br-cAMP)-stimulated cells was assessed using 5% plasma as the 
acceptor. For this, the incubation with OptiMem was replaced 
with DMEM containing 0.2% fatty acid-free BSA and 0.3 mM 
8Br-cAMP.
For all three types of assays, radioactivity was measured in both 
supernatant and cells. Cholesterol efflux was calculated as the 
percentage of labeled cholesterol released to the medium divided 
by the amount of total labeled cholesterol in the medium and 
cells in each well. To control for inter-assay plate variability, stan-
dard pooled plasma was prepared from several healthy (non-
pregnant) volunteers and run on each plate as a reference; all 
assay plates were processed together in a single run. Both intra- 
and inter-assay coefficients of variation were <5%.
Quantification of apoA1 and apoE
apoA1 and apoE concentrations were determined in plasma 
using ELISA kits following the manufacturer’s protocol (apoA1, 
3710-1HP-2; apoE, 3712-1HP-2; Mabtech, Nacka Strand, Sweden). 
The inter- and intra-assay coefficients of variation were: apoA1, 
2.5% and 2.2% and apoE, 2.5% and 2.8%, respectively.
Cholesterol concentrations
The lipoproteins (LDL, HDL, TC, and TG) were measured in 
serum as previously described (21) using MicroSlide technology 
on the Vitros Fusion 5.1 chemistry system (New York, NY). All 
samples were analyzed in triplicate, with the inter-assay variation 
being less than 10% and the intra-assay variation less than 5%.
The 27-OHC concentrations
The 27-OHC was quantified by GC-MS in plasma (28) and pla-
centa. For plasma, 200 l were used. The volume was adjusted to 
500 l with saline and 100 l butylated hydroxytoluene in 1% 
pyridine were added to avoid auto-oxidation. One hundred 
nanograms of 5-cholestan-3,6-diol were used as an internal 
standard. Saponification was performed with 1.5 ml of ethanolic 
NaOH 1 M for 2 h at 50°C, neutralized with 1 ml of phosphate 
buffer 0.1 M (pH 7.0), and pH adjusted to 7 with phosphoric 
acid. Samples were centrifuged for 5 min at 1,000 g and superna-
tants were harvested for the following clean-up procedure per-
formed by solid-phase extraction: Sep Pak C18 cartridges were 
preconditioned with n-heptane/2-propanol (1:1, v/v), metha-
nol, and water before application of the supernatants. The car-
tridges were washed with methanol/water (3:1, v/v) and dried 
with nitrogen. The 27-OHC was eluted by n-heptane/2-propanol 
(1:1) in a tube containing 100 l butylated hydroxytoluene in 1% 
pyridine and 100 ng of stigmasterol as a standard for chromatog-
raphy and derivatization. After evaporation of the solvent under 
nitrogen, samples were derivatized with 100 l pyridine and 100 l 
N,O-bis-trimethylsilyl-trifluoroacetamide for 1 h at 60°C (29, 30). 
Samples were diluted with 200 l of cyclohexane and analyzed 
by GC-MS by selected ion monitoring. A standard curve con-
taining a mixture of known amounts of each 27-OHC was 
performed.
For 27-OHC quantification in placenta, 100 mg powdered tis-
sue was homogenized in 1 ml potassium phosphate buffer (pH 7.2) 
(containing 300 mM sucrose, 0.5 mM dithiothreitol, 10 mM 
EDTA) and 100 l butylated hydroxytoluene in 1% pyridine, in 
Lysing matrix tubes (MPI, Lucerna Chem AG, Switzerland). Cell 
debris was removed by centrifugation at 1,500 g for 1 min. The 
supernatant was collected, 100 ng internal standard (5-cholestan-
3,6-diol) were added, and lipids were extracted with 19 vol 
chloroform/methanol (2:1, v/v) for 30 min. Samples were centri-
fuged at 2,000 g for 5 min and the lipid-containing chloroform 
layer was collected and transferred into a fresh tube containing 
100 l butylated hydroxytoluene in 1% pyridine. Solid phase ex-
traction, desorption, and derivatization were performed as de-
scribed for plasma.
CYP27A1 activity was determined in plasma by calculating the 
ratios of 27-OHC/(27-OHC + cholesterol). Cholesterol values 
were previously measured and reported in these samples (21).
RNA extraction, cDNA synthesis, and quantitative  
real-time PCR
Total RNA was extracted from 100 mg placental tissue using 
QIAzol lysis reagent (Qiagen, UK), as previously described (31). 
RNA (1 g) was reverse transcribed using the QuantiTect reverse 
transcription kit (Qiagen) in a Primus96 thermocycler (Peqlab 
Ltd., UK).
Real-time PCR was carried out using SYBR Green chemistry (2× 
QuantiFast SYBR Green; Qiagen) on an AB7500 Fast (Life Tech-
nologies, UK) using the primers in supplemental Table S1. Abun-
dance data for the genes of interest were expressed following 
normalization using GeNORM (https://genorm.cmgg.be/), with 
stably expressed housekeeping genes (GAPDH, -2-microglobulin, 
and -actin) expressed as normalized copy number.
Immunohistochemical staining
Placental protein expression was analyzed by immunohisto-
chemistry, as previously described (31), using CYP27A1 rabbit 
(14739-1-AP; dilution 1:20; Proteintech), AIBP goat (sc-161321; 
dilution 1:50; Santa Cruz Biotechnology), SRB1 rabbit (SAB3500048; 
dilution 1:600; Sigma-Aldrich, UK), and apoA1 rabbit (A8599; dilu-
tion 1:300; Sigma-Aldrich) polyclonal antibodies and apoE mouse 
(HPA001352; dilution 1:250; Sigma-Aldrich) monoclonal antibody. 
All of the slides were assessed by the same observer, blinded to 
pregnancy outcome. Quantification was performed as described 
previously (31), using the Positive Pixel Algorithm of Aperio 
ImageScope software; a visual check was also performed.
Statistical analysis
All tests were performed using SPSS version 22. Summary data 
are presented as mean ± SD or median and interquartile range 
TABLE 2. Clinical and obstetrics data of the preeclamptic women 
delivery AGA and SGA infants
Parameter PE-AGA (n = 11) PE-SGA (n = 6)
Age (years) 30.6 ± 7.1 31.5 ± 3.9
Gestational age at delivery (weeks) 38.8 ± 1.2 36.5 ± 2.4
Mean birthweight (g) 3,505 ± 658 2,175 ± 611a 
Corrected birthweight centile 64.5 [33.5, 86.2] 4.1 [0.5, 8.5]a
Data represented as mean ± SD or median [IQR] as appropriate. 
PE, preeclampsia.
aP < 0.05 between PE-AGA and PE-SGA.
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(IQR) as appropriate. The Kruskal-Wallis test, followed by Mann-
Whitney U-test was used for multiple group analysis. The Student’s 
t-test or Mann-Whitney U-tests were used depending on the distri-
bution of the data, after testing using the Kolmogorov-Smirnov 
test. The null hypothesis was rejected where P < 0.05.
RESULTS
Subjects
The demographic and obstetric data of the 34 partici-
pants are shown in Table 1. Within the preeclamptic group, 
6 women delivered SGA infants and 11 delivered AGA in-
fants (Table 2); no woman in the normotensive control 
group delivered an SGA infant.
Cholesterol efflux
Cholesterol efflux capacity of both maternal and fetal 
plasma was increased in preeclampsia (by 10.2% and 9.3%, 
respectively; P < 0.05 for both; Fig. 1A); cholesterol efflux 
capacity was lower in fetal compared with maternal plasma 
in both study groups (31% and 24%, respectively; P < 0.001 
for both; Fig. 1A). In addition, the same differences were 
observed when HDL-mediated cholesterol efflux capacity 
was performed with apoB-depleted plasma as an acceptor 
[increased in preeclamptics by maternal (19.3%) and fetal 
(12.7%); Fig. 1B]. Conversely, both maternal and fetal 
ABCA1-mediated efflux was significantly reduced in the 
preeclampsia samples (by 35% and 20%, respectively; 
P < 0.05; Fig. 1C). Data of the cholesterol efflux capacity of 
stimulated and nonstimulated cells can be seen in supple-
mental Fig. S1.
Despite no differences being observed in the maternal 
cholesterol efflux capacity between groups (Fig. 2A), the 
fetal cholesterol efflux capacity was lower in SGA com-
pared with AGA infants only within the preeclamptic group 
(median [IQR]; SGA, 2.3 [2.1, 2.3]; AGA, 2.6 [2.4, 3.2] per-
cent cholesterol efflux; P < 0.05; Fig. 2B).
apoA1 and apoE concentrations
Maternal apoA1 concentrations were higher than fetal 
concentrations in both groups (P < 0.05; Table 3); no dif-
ferences were observed for either maternal or fetal apoA1 
between normotensive control and preeclamptic women 
(P > 0.05 for all; Table 3).
Maternal plasma apoE was higher than fetal apoE only in 
preeclampsia (P < 0.0001; Table 3). apoE concentrations 
Fig. 1. Cholesterol efflux with maternal and fetal 
plasma. A: Cholesterol efflux capacity (percent). B: 
HDL-mediated (PEG treated) cholesterol efflux (per-
cent). C: ABCA1-mediated cholesterol efflux from 
normotensive controls (NC) and preeclamptic (PE) 
plasma. Data are represented as median [IQR]; 
*P < 0.05; **P < 0.001; ***P < 0.0001.
Fig. 2. Cholesterol efflux capacity and apoE in PE 
with AGA or SGA. Maternal (A) and fetal (B) choles-
terol efflux was quantified in preeclamptic pregnan-
cies from AGA (n = 11) and SGA (n = 6). apoE was 
quantified in maternal (C) and fetal (D) plasma from 
preeclamptic pregnancies with and without SGA. Data 
are represented as median [IQR]; *P < 0.05.
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were higher in maternal and fetal plasma in the preeclamp-
sia group (P < 0.05; Table 3). In the preeclamptic group, 
maternal apoE was not changed for SGA infants (Fig. 2C), 
but fetal apoE was lower in SGA compared with AGA in-
fants (median [IQR]; SGA, 0.42 [0.37, 0.47] g/l; AGA, 0.56 
[0.48, 0.64] g/l; P < 0.05; Fig. 2D).
Lipoprotein and 27-OHC concentrations
As previously reported (21), circulating TC, TGs, and li-
poproteins were not significantly different between groups, 
although lower levels were observed in both the fetal 
normotensive control and preeclamptic groups compared 
with the maternal samples (Table 3).
We analyzed 27-OHC concentration as a marker of 
CYP27A1 activity: this was reduced in fetal compared with 
maternal plasma, irrespective of diagnostic pregnancy 
group (Fig. 3A, B). Maternal 27-OHC was slightly, but not 
significantly, higher in preeclampsia (Fig. 3A). Fetal 27-OHC, 
however, was significantly reduced in the preeclamptic 
group (P < 0.05; Fig. 3B). CYP27A1 activity [assessed by the 
ratio of 27-OHC/(27-OHC + cholesterol)] was unchanged 
between normotensive women and those with preeclamp-
sia in both maternal (mean ± SD; 0.97 ± 0.01 ng/ml vs. 
0.97 ± 0.03 ng/ml) and fetal (0.97 ± 0.02 ng/ml vs. 0.96 ± 
0.02 ng/ml) plasma (P > 0.05 for both).
Placental 27-OHC concentrations were significantly in-
creased in tissues obtained from preeclamptic mothers 
(mean ± SD; normotensive controls, 15.1 ± 1.8 ng/ml; pre-
eclampsia, 17.2 ± 3.4 ng/ml; P < 0.05; Fig. 3C).
Placental CYP27A1, AIBP, apoA1, apoE, and SCB1 
expression
Expression of both CYP27A1 and AIBP mRNA was de-
tected in placental tissue, but there were no significant 
differences between groups for both (median [IQR] nor-
malized copy numbers; normotensive controls vs. pre-
eclampsia) CYP27A1 (1,201 [293, 2,667] vs. 1,013 [677, 
6,657]) or AIBP (284 [154, 526] vs. 310 [220, 616]); 
P > 0.05 for both.
CYP27A1 protein was localized by immunohistochem-
istry around fetal vessels and in Hofbauer cells (Fig. 4). 
CYP27A1 protein expression was increased in pre-
eclampsia (mean ± SD; preeclampsia 0.06 ± 0.07; normo-
tensive controls, 0.02 ± 0.02; P = 0.04; Fig. 4). Within the 
preeclamptic group, CYP27A1 expression was higher in 
pregnancies delivering SGA compared with AGA infants 
(mean ± SD; SGA, 0.11 ± 0.01; AGA, 0.04 ± 0.04; P = 0.02). 
No differences were observed between early- and late-
onset preeclampsia and normotensive controls (ANOVA: 
P > 0.05).
AIBP protein was localized to fetal vessels and syncytio-
trophoblasts (Fig. 5). AIBP protein expression was also in-
creased in preeclampsia compared with the control group 
(mean ± SD; preeclampsia, 0.78 ± 0.10; normotensive con-
trols, 0.66 ± 0.14; P = 0.004; Fig. 5). No differences were 
found between preeclamptic women delivering an AGA or 
SGA infant (P > 0.05).
TABLE 3. Maternal and fetal lipoprotein, apoA1, and apoE 
concentration
Parameter NC (n = 17) PE (n = 17)
Lipoprotein concentrations (mmol/l)a 
 Maternal TC 5.6 ± 2.2 6.4 ± 1.1
 Fetal TC 2.6 ± 1.5b 1.7 ± 0.3b
 Maternal TGs 2.2 ± 0.7 2.6 ± 0.6
 Fetal TGs 1.1 ± 0.9b 0.7 ± 0.9b
 Maternal HDL 1.5 ± 0.3 1.4 ± 0.9
 Fetal HDL 0.9 ± 0.4b 0.6 ± 0.1b
 Maternal LDL 3.5 ± 1.9 3.8 ± 0.1
 Fetal LDL 1.2 ± 0.8b 0.8 ± 0.3b
apoA1 and apoE concentrations (g/l)
 Maternal apoA1 19.3 ± 9.3 23.6 ± 7.4
 Fetal apoA1 2.4 ± 0.9b 2.8 ± 1.4b
 Maternal apoE 0.6 ± 0.4 1.0 ± 0.5c
 Fetal apoE 0.4 ± 0.1 0.5 ± 0.1b,c
Data represented as mean ± SD. NC, normotensive control; PE, 
preeclampsia; OHC, hydroxycholesterol.
a Lipoprotein concentrations previously measured (21).
bP < 0.05 between maternal and fetal samples.
cP < 0.05 between normotensive controls and women with 
preeclampsia.
Fig. 3. Quantification of 27-OHC in maternal plasma 
(A), fetal plasma (B), and placental tissue (C). The 
27-OHC concentrations were quantified by GC-MS in 
plasma from normotensive controls (NC) and pre-
eclamptics (PE). In the graphs data are represented as 
mean ± SD; *P < 0.05.
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Protein expression of apoA1, apoE, and SCB1 was also 
confirmed and localized to syncytiotrophoblasts; there 
were no differences between groups for any of these pro-
teins (P > 0.05; data not shown).
DISCUSSION
It is currently recognized that women who develop pre-
eclampsia have an increased risk of developing atheroscle-
rosis later on in life (32). Low birth weight is one of the 
classic risk factors for developing CVD in adult life: chil-
dren born to women who experience preeclampsia in their 
pregnancy are susceptible to these risk factors in such a way 
as to develop increased BMI and hypertension at an earlier 
stage in adulthood than may otherwise occur purely due to 
aging (33).
Therefore in this study, we compared normotensive 
women to those with preeclampsia, analyzing the ability of 
maternal and fetal plasma to remove cholesterol from the 
cell. We further supplemented our previous lipid profile 
analyses by quantifying 27-OHC in plasma and CYP27A1 
activity, and by assessing the efflux capacity of plasma un-
der various conditions. Additionally, we were able to assess 
the concentration of 27-OHC in matched placental tissue. 
This is a novel and detailed study of placental CYP27A1, 
27-OHC, and AIBP proteins, strengthened by the determi-
nation of cholesterol efflux capacity in matched maternal 
and fetal plasma samples.
It is well-established that in addition to hypertension, al-
tered cholesterol metabolism is also linked to cardiovascu-
lar events. In nonpregnant individuals, a low level of HDL-C 
is a major independent risk factor for atherosclerotic CVD 
(34). However, randomized clinical trials aimed at improv-
ing HDL-C concentrations have not shown any significant 
protective effect in cardiovascular outcomes (35), strongly 
suggesting the importance of alternative mechanisms or 
combinations of diagnostic biomarkers. It has recently 
been advocated that a more important factor may actually 
be the ability of HDL-C to act as an acceptor for the choles-
terol discharged from macrophages. Cholesterol efflux is 
the first and rate limiting step of RCT (22) and animal 
studies support a direct and causal link between macro-
phage-specific cholesterol efflux capacity and prevention 
of atherosclerosis (36). Furthermore, studies have revealed 
inverse relationships between cholesterol efflux capacity 
and prevalent coronary artery disease, which are inde-
pendent of HDL-C levels (37). The role of CYP27A1 in 
Fig. 4. Localization and quantification of placental 
CYP27A1 immunostaining in placentae from normo-
tensive controls (NC; n = 17) (A), preeclampsia (PE; 
n = 17) (B), and negative control (C). In photomicro-
graphs, positive cells appear in brown; magnification 
×400. Protein expression was localized to Hofbauer 
cells (black arrows) and fetal vessels (red arrows). In 
the graph (D), data are represented as mean ± SD; 
*P < 0.05.
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cholesterol efflux has been shown (8), and the deleterious 
effect of its mutation in patients with cerebrotendinous 
xanthomatosis underlines the importance of this enzyme 
in RCT and atherosclerosis prevention.
The increased maternal and fetal cholesterol efflux ca-
pacity in the preeclamptic group suggests a potential adap-
tation to extrude cholesterol out of cells in preeclampsia. It 
is conceivable that a reduction in the oxidation of LDL-C 
would result in attenuation of lipid peroxidation (Fig. 6). 
We have previously reported that these fetal samples had 
lower circulating HDL-C concentrations (21), but when 
corrected for HDL concentrations, the differences in ef-
flux capacity remained, as did the HDL-mediated efflux. 
Thus, we might hypothesize that the increased cholesterol 
efflux capacity in both the women with preeclampsia and 
their fetuses could be a protective mechanism to prevent 
excessive lipid peroxidation in these babies. In light of the 
fact that overall cholesterol efflux capacity is increased in 
preeclampsia, the specific reduction in ABCA1-mediated 
cholesterol efflux in preeclampsia suggests that other com-
ponents of this efflux system may be increased in order to 
compensate. Because apoE complexed to HDL-C has also 
been reported to promote cholesterol efflux (38), and as 
apoE is increased in our preeclampsia group, both mater-
nal and fetal, the apoE-mediated efflux might counteract 
the reduction in ABCA1-mediated efflux. The increased 
apoE levels may also have a positive contribution toward 
offsetting the oxidative stress and inflammatory states re-
ported in preeclampsia (39), through its reported antioxi-
dant and anti-inflammatory role (40).
The localization of CYP27A1 protein, around fetal 
vessels and within Hofbauer cells in the placenta, also 
points toward a functional role in the cholesterol efflux 
process facilitating the removal of the cholesterol from the 
tissue via the vascular circulation. The increased placental 
CYP27A1 expression and production of 27-OHC in pre-
eclampsia may reflect placental dysfunction, contributing 
to increased lipid peroxidation within the tissue. Further-
more, placental ABCA1 is known to be downregulated in 
preeclampsia (41); thus, increased CYP27A1 activity could, 
at least in part, contribute to a protective mechanism 
by providing sufficient ligand to activate the LXR-ABCA1 
pathway.
In addition, the higher placental CYP27A1 in preeclamp-
tic women delivering SGA infants further supports the no-
tion of inappropriate fetal cholesterol uptake in these cases. 
Higher fetal and placental oxidized LDL-C concentrations 
have been reported from women delivering fetal growth 
restriction infants (42), suggesting a disturbed cholesterol 
supply to these affected fetuses. Our current study further 
Fig. 5. Localization and quantification of placental 
AIBP immunostaining in placentae from normoten-
sive controls (NC; n = 17) (A), preeclampsia (PE; n = 
17) (B), and negative control (C). In photomicro-
graphs, positive cells appear in brown; magnification 
×400. Protein expression was localized to fetal vessels 
(red arrows) and syncytiotrophoblasts (blue arrows). 
In the graph (D), data are represented as mean ± SD; 
**P < 0.001.
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strengthens this hypothesis reporting even further reduc-
tion of fetal cholesterol efflux and apoE concentration in 
SGA babies from women experiencing preeclampsia in 
their pregnancy.
Fang et al. (14) have recently reported that effective cho-
lesterol efflux is critical for proper angiogenesis. They ob-
served that both AIBP- and HDL-C-mediated cholesterol 
efflux alters the composition of the lipid rafts due to re-
duced CAV-1, as well as interfering with VEGFR1 (KDR) 
dimerization and signaling, thus inhibiting VEGF-induced 
angiogenesis (14, 15). The authors concluded that AIBP 
positively regulates cholesterol efflux from endothelial 
cells and that effective cholesterol efflux is critical for 
proper angiogenesis (14). Our current result demonstrat-
ing increased placental AIBP together with our previously 
observed reduction in placental CAV-1 expression in pre-
eclampsia (43) and the reported reduction of VEGFR2 (44), 
all considered together, intimate at an inappropriate lipid 
homeostasis. This may inhibit/disrupt placental angiogen-
esis, contributing to the endothelial dysfunction that is 
Fig. 6. Schematic diagram illustrating the changes 
observed in preeclampsia to suggest a potential link 
between changes in cholesterol efflux and the altera-
tion in cholesterol metabolism. The raised placental 
AIBP may contribute to the impaired angiogenesis/
extravillous trophophlast (EVT) invasion, possibly 
leading to increased oxidative stress and endothelial 
dysfunction. In contrast, the increased placental 
CYP27A1, which parallels the increased 27-OHC pla-
centa concentration may lead to the increased choles-
terol efflux observed, thus dampening the lipid 
peroxidation and associated oxidative stress/endothe-
lial dysfunction, providing a compensatory response.
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these women and their offspring, both in the short- and 
long-term. Exploring alterations in their cholesterol efflux 
capacity in combination with other known risk factors may 
provide a novel and more accurate biomarker for predic-
tion of CVD.
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characteristic of preeclampsia. The raised expression in 
early-onset preeclampsia further supports this theory, as pla-
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changes in protein half-life in preeclampsia contributing to 
the lipid peroxidation. This is further substantiated by the 
additional increases in protein expression of CYP27A1 and 
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ously associated with increased lipid peroxidation, further 
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tinue postpartum, but further work is required to test this 
hypothesis.
Figure 6 summarizes the potential mechanisms relating 
CYP27A1, 27-OHC, and cholesterol efflux capacity in pre-
eclampsia. The raised placental AIBP may contribute to 
the impaired angiogenesis and extravillous trophoblast in-
vasion, possibly leading to increased oxidative stress and 
endothelial dysfunction. In contrast, the increased placen-
tal CYP27A1, which parallels the increased 27-OHC pla-
centa concentration, may lead to the observed increased 
cholesterol efflux, thus trying to dampen the lipid peroxi-
dation and associated oxidative stress/endothelial dysfunc-
tion, providing a compensatory response.
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